DJIA 17,827.75 12.81 0.07%
NASDAQ 4,787.32 29.07 0.61%
S&P 500 2,072.83 5.80 0.28%
market minute promo

Exelixis (NASDAQ: EXEL)



company name or ticker

Exelixis: Why This Company Could Become The Next Dendreon

Update: Exelixis Announces Very Positive Phase 1 Trial Data

Biotech Weekly: Here Come The Institutional Holdings Updates

Update: Exelixis Reports Q3 Earnings - Impact To My Thesis

Exelixis' (EXEL) CEO Mike Morrissey on Q3 2014 Results - Earnings Call Transcript

Exelixis' Cometriq Makes a Comeback

Exelixis reports third quarter earnings, but it's the data testing Cometriq in lung cancer that's caused the stock pop.

Exelixis (EXEL) Q3 2014 Results - Earnings Call Webcast

Why Exelixis, Inc. Stock Pushed 11% Higher in October

Exelixis was one of the best biotech stocks in October. Find out what sent its shares higher by 11% and whether or not the good times will keep rolling for this small-cap biotech stock.

Will Exelixis (EXEL) Disappoint This Earnings Season? - Analyst Blog

Is Exelixis, Inc. Stock a Bad News Buy?

Is the 75% drop in Exelixis, Inc. stock justified? Two of our top analysts weigh in and discuss the company's potential as a "bad news buy".
See More Articles...